{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T04:02:03Z","timestamp":1779940923490,"version":"3.53.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02791-5","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T03:02:59Z","timestamp":1779937379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phosphoproteomics distinguishes disease-specific mechanisms for human phospholamban cardiomyopathy reversible by RNA therapy"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9793-4683","authenticated-orcid":false,"given":"Frederik E.","family":"Deiman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5926-6960","authenticated-orcid":false,"given":"Nils","family":"B\u00f6mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Davidsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Sp\u00e4ter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annet N.","family":"Linders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itamar B.","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla F.","family":"Arevalo Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Esquivel Gaytan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Walentinsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Engberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Hattersley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damla","family":"Etal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Ahlstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4600-961X","authenticated-orcid":false,"given":"Adam E.","family":"Mullick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenny M.","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman H. W.","family":"Sillj\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Grote Beverborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"2791_CR1","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nrm1151","volume":"4","author":"DH MacLennan","year":"2003","unstructured":"MacLennan, D. H. & Kranias, E. G. Phospholamban: a crucial regulator of cardiac contractility. Nat. Rev. Mol. Cell Biol. 4, 566\u2013577 (2003).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2791_CR2","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s12471-013-0401-3","volume":"21","author":"PA van der Zwaag","year":"2013","unstructured":"van der Zwaag, P. A. et al. Recurrent and founder mutations in the Netherlands-Phospholamban p.Arg14del mutation causes arrhythmogenic cardiomyopathy. Neth. Heart J. 21, 286\u2013293 (2013).","journal-title":"Neth. Heart J."},{"key":"2791_CR3","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1093\/eurjhf\/hfs119","volume":"14","author":"PA van der Zwaag","year":"2012","unstructured":"van der Zwaag, P. A. et al. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur. J. Heart Fail. 14, 1199\u20131207 (2012).","journal-title":"Eur. J. Heart Fail."},{"key":"2791_CR4","doi-asserted-by":"crossref","unstructured":"Deiman, F. E. et al. Plasma proteomics stratification identifies phospholamban R14del carriers at risk for disease progression. Cardiovasc. Res. cvag089 (2026).","DOI":"10.1093\/cvr\/cvag089"},{"key":"2791_CR5","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s11897-022-00558-x","volume":"19","author":"FE Deiman","year":"2022","unstructured":"Deiman, F. E., Bomer, N., van der Meer, P. & Grote Beverborg, N. Review: precision medicine approaches for genetic cardiomyopathy: targeting phospholamban R14del. Curr. Heart Fail. Rep. 19, 170\u2013179 (2022).","journal-title":"Curr. Heart Fail. Rep."},{"key":"2791_CR6","first-page":"1","volume":"10","author":"TR Eijgenraam","year":"2020","unstructured":"Eijgenraam, T. R. et al. The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unresponsive to standard heart failure therapy. Sci. Rep. 10, 1\u201313 (2020).","journal-title":"Sci. Rep."},{"key":"2791_CR7","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202013074","volume":"13","author":"F Cuello","year":"2021","unstructured":"Cuello, F. et al. Impairment of the ER\/mitochondria compartment in human cardiomyocytes with PLN p.Arg14del mutation. EMBO Mol. Med. 13, e13074 (2021).","journal-title":"EMBO Mol. Med."},{"key":"2791_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7955","volume":"6","author":"I Karakikes","year":"2015","unstructured":"Karakikes, I. et al. Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy. Nat. Commun. 6, 6955 (2015).","journal-title":"Nat. Commun."},{"key":"2791_CR9","doi-asserted-by":"publisher","first-page":"13500","DOI":"10.3390\/ijms222413500","volume":"22","author":"B Badone","year":"2021","unstructured":"Badone, B. et al. Characterization of the PLN p.Arg14del mutation in human induced pluripotent stem cell-derived cardiomyocytes. Int. J. Mol. Sci. 22, 13500 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2791_CR10","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1161\/CIRCULATIONAHA.120.049844","volume":"144","author":"DAM Feyen","year":"2021","unstructured":"Feyen, D. A. M. et al. Unfolded protein response as a compensatory mechanism and potential therapeutic target in PLN R14del cardiomyopathy. Circulation 144, 382\u2013392 (2021).","journal-title":"Circulation"},{"key":"2791_CR11","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/his.12963","volume":"69","author":"WP te Rijdt","year":"2016","unstructured":"te Rijdt, W. P. et al. Phospholamban p.Arg14del cardiomyopathy is characterized by phospholamban aggregates, aggresomes, and autophagic degradation. Histopathology 69, 542\u2013550 (2016).","journal-title":"Histopathology"},{"key":"2791_CR12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1007\/s00018-024-05471-1","volume":"81","author":"E Vafiadaki","year":"2024","unstructured":"Vafiadaki, E., Kranias, E. G., Eliopoulos, A. G. & Sanoudou, D. The phospholamban R14del generates pathogenic aggregates by impairing autophagosome-lysosome fusion. Cell. Mol. Life Sci. 81, 450 (2024).","journal-title":"Cell. Mol. Life Sci."},{"key":"2791_CR13","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1161\/CIRCRESAHA.123.323304","volume":"133","author":"NM Stege","year":"2023","unstructured":"Stege, N. M. et al. DWORF extends life span in a PLN-R14del cardiomyopathy mouse model by reducing abnormal sarcoplasmic reticulum clusters. Circ. Res. 133, 1006\u20131021 (2023).","journal-title":"Circ. Res."},{"key":"2791_CR14","first-page":"1014","volume":"9","author":"NM Stege","year":"2024","unstructured":"Stege, N. M., de Boer, R. A., Makarewich, C. A., van der Meer, P. & Sillj\u00e9, H. H. W. Reassessing the mechanisms of PLN-R14del cardiomyopathy: from calcium dysregulation to S\/ER malformation. JACC Basic Transl. Sci. 9, 1014\u20131052 (2024).","journal-title":"JACC Basic Transl. Sci."},{"key":"2791_CR15","doi-asserted-by":"publisher","first-page":"E008532","DOI":"10.1161\/CIRCHEARTFAILURE.121.008532","volume":"14","author":"TR Eijgenraam","year":"2021","unstructured":"Eijgenraam, T. R. et al. Protein aggregation is an early manifestation of phospholamban p.(Arg14del)-related cardiomyopathy: development of PLN-R14del-related cardiomyopathy. Circ. Heart Fail. 14, E008532 (2021).","journal-title":"Circ. Heart Fail."},{"key":"2791_CR16","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1161\/01.RES.76.6.1028","volume":"76","author":"R Zhang","year":"1995","unstructured":"Zhang, R., Zhao, J., Mandveno, A. & Potter, J. D. Cardiac troponin I phosphorylation increases the rate of cardiac muscle relaxation. Circ. Res. 76, 1028\u20131035 (1995).","journal-title":"Circ. Res."},{"key":"2791_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1113\/jphysiol.2003.046367","volume":"552","author":"D Terentyev","year":"2003","unstructured":"Terentyev, D., Viatchenko-Karpinski, S., Gyorke, I., Terentyeva, R. & Gyorke, S. Protein phosphatases decrease sarcoplasmic reticulum calcium content by stimulating calcium release in cardiac myocytes. J. Physiol. 552, 109\u2013118 (2003).","journal-title":"J. Physiol."},{"key":"2791_CR18","doi-asserted-by":"publisher","first-page":"e104157","DOI":"10.1371\/journal.pone.0104157","volume":"9","author":"MA Schechter","year":"2014","unstructured":"Schechter, M. A. et al. Phosphoproteomic profiling of human myocardial tissues distinguishes ischemic from non-ischemic end stage heart failure. PLoS ONE 9, e104157 (2014).","journal-title":"PLoS ONE"},{"key":"2791_CR19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2212118120","volume":"120","author":"CJ Reitz","year":"2023","unstructured":"Reitz, C. J. et al. Proteomics and phosphoproteomics of failing human left ventricle identifies dilated cardiomyopathy-associated phosphorylation of CTNNA3. Proc. Natl. Acad. Sci. USA 120, e2212118120 (2023).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2791_CR20","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/nature08908","volume":"463","author":"DA Fletcher","year":"2010","unstructured":"Fletcher, D. A. & Mullins, R. D. Cell mechanics and the cytoskeleton. Nature 463, 485\u2013492 (2010).","journal-title":"Nature"},{"key":"2791_CR21","doi-asserted-by":"publisher","first-page":"102767","DOI":"10.1016\/j.jbc.2022.102767","volume":"299","author":"IR Sevrieva","year":"2022","unstructured":"Sevrieva, I. R. et al. Phosphorylation-dependent interactions of myosin-binding protein C and troponin coordinate the myofilament response to protein kinase A. J. Biol. Chem. 299, 102767 (2022).","journal-title":"J. Biol. Chem."},{"key":"2791_CR22","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.bpj.2012.12.021","volume":"104","author":"AJ Michalek","year":"2013","unstructured":"Michalek, A. J. et al. Phosphorylation modulates the mechanical stability of the cardiac myosin-binding protein C motif. Biophys. J. 104, 442\u2013452 (2013).","journal-title":"Biophys. J."},{"key":"2791_CR23","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1007\/s12265-025-10717-9","volume":"18","author":"FE Deiman","year":"2025","unstructured":"Deiman, F. E. et al. RNA therapeutics in heart failure. J. Cardiovasc. Transl. Res. 18, 1540\u20131554 (2025).","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"2791_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25439-0","volume":"12","author":"N Grote Beverborg","year":"2021","unstructured":"Grote Beverborg, N. et al. Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy. Nat. Commun. 12, 5180 (2021).","journal-title":"Nat. Commun."},{"key":"2791_CR25","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1093\/cvr\/cvaf156","volume":"121","author":"L Sun","year":"2025","unstructured":"Sun, L. et al. In PLN-R14del mice, SR structure restoration, rather than calcium cycling, is the dominant effector of PLN-ASO treatment. Cardiovasc. Res. 121, 2042 (2025).","journal-title":"Cardiovasc. Res."},{"key":"2791_CR26","doi-asserted-by":"publisher","first-page":"966094","DOI":"10.3389\/fcvm.2022.966094","volume":"9","author":"L Reilly","year":"2022","unstructured":"Reilly, L., Munawar, S., Zhang, J., Crone, W. C. & Eckhardt, L. L. Challenges and innovation: disease modeling using human-induced pluripotent stem cell-derived cardiomyocytes. Front. Cardiovasc. Med. 9, 966094 (2022).","journal-title":"Front. Cardiovasc. Med."},{"key":"2791_CR27","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1161\/01.RES.86.8.846","volume":"86","author":"A Heling","year":"2000","unstructured":"Heling, A. et al. Increased expression of cytoskeletal, linkage, and extracellular proteins in failing human myocardium. Circ. Res. 86, 846\u2013853 (2000).","journal-title":"Circ. Res."},{"key":"2791_CR28","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/s41569-022-00692-y","volume":"19","author":"MA Caporizzo","year":"2022","unstructured":"Caporizzo, M. A. & Prosser, B. L. The microtubule cytoskeleton in cardiac mechanics and heart failure. Nat. Rev. Cardiol. 19, 364\u2013378 (2022).","journal-title":"Nat. Rev. Cardiol."},{"key":"2791_CR29","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0008-6363(99)00268-0","volume":"45","author":"S Hein","year":"2000","unstructured":"Hein, S., Kostin, S., Heling, A., Maeno, Y. & Schaper, J. The role of the cytoskeleton in heart failure. Cardiovasc. Res. 45, 273\u2013278 (2000).","journal-title":"Cardiovasc. Res."},{"key":"2791_CR30","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.hlc.2014.02.009","volume":"23","author":"HM Viola","year":"2014","unstructured":"Viola, H. M. & Hool, L. C. How does calcium regulate mitochondrial energetics in the heart? - New insights. Heart Lung Circ. 23, 602\u2013609 (2014).","journal-title":"Heart Lung Circ."},{"key":"2791_CR31","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1172\/JCI17892","volume":"111","author":"K Haghighi","year":"2003","unstructured":"Haghighi, K. et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J. Clin. Invest. 111, 869\u2013876 (2003).","journal-title":"J. Clin. Invest."},{"key":"2791_CR32","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s12471-025-01941-8","volume":"33","author":"FE Deiman","year":"2025","unstructured":"Deiman, F. E. et al. Identification of disease-specific pathways and modifiers in phospholamban R14del cardiomyopathy: rationale, design and baseline characteristics of DECIPHER-PLN cohort. Neth. Heart J. 33, 112 (2025).","journal-title":"Neth. Heart J."},{"key":"2791_CR33","doi-asserted-by":"publisher","first-page":"MSB199021","DOI":"10.15252\/msb.20199021","volume":"15","author":"M Leutert","year":"2019","unstructured":"Leutert, M., Rodr\u00edguez-Mias, R. A., Fukuda, N. K. & Vill\u00e9n, J. R2-P2 rapid-robotic phosphoproteomics enables multidimensional cell signaling studies. Mol. Syst. Biol. 15, MSB199021 (2019).","journal-title":"Mol. Syst. Biol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02791-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02791-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02791-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T03:03:06Z","timestamp":1779937386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02791-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2791"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02791-5","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was supported by a research grant from AstraZeneca. Frederik Deiman, Annet Linders, Itamar Dias, Karla Arevalo Gomez, Antonio Esquivel Gaytan, Jumo Zhu, Nils B\u00f6mer, and Niels Grote Beverborg declare no conflict of interest. Herman Sillj\u00e9 reports grants from AstraZeneca, Novo Nordisk and Pfizer outside the submitted work. Peter van der Meer reports grants from AstraZeneca, Ionis Pharmaceuticals, Novo Nordisk, Novartis, Pharmacosmos, Vifor Pharma, Pfizer, Pharma Nord, and BridgeBio outside the submitted work. Pia Davidsson, Daniela Sp\u00e4ter, Anna Walentinsson, Susanna Engberg, Neil Hattersley, Damla Etal, Christine Ahlstrom and Kenny Hansson are employed by AstraZeneca. Adam Mullick is employed by Ionis Pharmaceuticals.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"199"}}